How far should we go? Perspective of drug-drug interaction studies in drug development

Drug Metabolism and Pharmacokinetics

Volumn 29, Issue 3, 2014, Pages 227-228

  Kusuhara, Hiroyuki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

16 M TOLYL 17,18,19,20 TETRANORISOCARBACYCLIN; 6BETA HYDROXYHYDROCORTISONE; 7 [3 (1 AMINOCYCLOPROPYL) 1 PYRROLIDINYL] 1 (2 FLUOROCYCLOPROPYL) 1,4 DIHYDRO 8 METHOXY 4 OXO 3 QUINOLINECARBOXYLIC ACID; BREAST CANCER RESISTANCE PROTEIN; CREATININE; CYTOCHROME P450 3A4; DRUG METABOLIZING ENZYME; ISOCARBACYCLIN; MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1; MULTIDRUG AND TOXIN EXTRUSION PROTEIN 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 3; N METHYLNICOTINAMIDE; ORGANIC CATION TRANSPORTER 2; PROBENECID; RIFAMPICIN; TRIMETHOPRIM; UNCLASSIFIED DRUG; DRUG;

CREATININE BLOOD LEVEL; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; DRUG INDUSTRY; DRUG INHIBITION; DRUG MARKETING; EDITORIAL; FOOD DRUG INTERACTION; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY CLEARANCE; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; METABOLOMICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARMACOLOGICAL SCIENCE; PRACTICE GUIDELINE; ANIMAL; DRUG DEVELOPMENT; DRUG INTERACTION; METABOLISM; PHYSIOLOGY; PROCEDURES;

ANIMALS; DRUG DISCOVERY; DRUG INTERACTIONS; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 84903618121     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-14-PF-903     Document Type: Editorial

References (7)

1. Takashima, T., Kitamura, S., Wada, Y., Tanaka, M., Shigihara, Y., Ishii, H., Ijuin, R., Shiomi, S., Nakae, T., et al.: PET imaging-based evaluation of hepatobiliary transport in humans with (15R)-11C-TIC-Me. J. Nucl. Med., 53: 741-748 (2012).
2. Galteau, M. M. and Shamsa, F.: Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur. J. Clin. Pharmacol., 59: 713-733 (2003).
3. Andreev, E., Koopman, M. and Arisz, L.: A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible? J. Intern. Med., 246: 247-252 (1999).
4. Ito, S., Kusuhara, H., Kumagai, Y., Moriyama, Y., Inoue, K., Kondo, T., Nakayama, H., Horita, S., Tanabe, K., et al.: N-methylnicotinamide is an endogenous probe for evaluation of drug-drug interactions involving multidrug and toxin extrusions (MATE1 and MATE2-K). Clin. Pharmacol. Ther., 92: 635-641 (2012).
5. Imamura, Y., Tsuruya, Y., Damme, K., Heer, D., Kumagai, Y., Maeda, K., Murayama, N., Okudaira, N., Kurihara, A., et al.: 6beta-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. Drug Metab. Dispos., 42: 685-694 (2014).
6. Krumpochova, P., Sapthu, S., Brouwers, J. F., de Haas, M., de Vos, R., Borst, P. and van de Wetering, K.: Transportomics: screening for substrates of ABC transporters in body fluids using vesicular transport assays. FASEB J., 26: 738-747 (2012).
7. Kato, K., Mori, H., Kito, T., Yokochi, M., Ito, S., Inoue, K., Yonezawa, A., Katsura, T., Kumagai, Y., et al.: Investigation of endogenous compounds for assessing the drug interactions in the urinary excretion involving multidrug and toxin extrusion proteins. Pharm. Res., 31: 136-147 (2014).